Utility of concentration‐effect modeling and simulation in a thorough QT study of losmapimod

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of clinical pharmacology

• Publication date

  2015-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/jcph.465PMID 25612153
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The IQ‐CSRC Prospective Clinical Phase 1 Study: “Can Early QT Assessment Using Exposure Response Analysis Replace the Thorough QT Study?”

  2014cited by this paper
• The Thorough QT Study: Is Its Demise on the Horizon?

  2014cited by this paper
• Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial.

  2014cited by this paper
• Losmapimod concentration–QT relationship in healthy volunteers: meta-analysis of data from six clinical trials

  2013cited by this paper
• Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis.

  2012cited by this paper
• Modelling the Double Peak Phenomenon in pharmacokinetics

  2011cited by this paper
• Population Pharmacokinetic and Concentration—QTc Models for Moxifloxacin: Pooled Analysis of 20 Thorough QT Studies

  2011cited by this paper
• Comparison of QTc Data Analysis Methods Recommended by the ICH E14 Guidance and Exposure–Response Analysis: Case Study of a Thorough QT Study of Asenapine

  2011cited by this paper
• Inhibition of p38 Mitogen-Activated Protein Kinase Improves Nitric Oxide–Mediated Vasodilatation and Reduces Inflammation in Hypercholesterolemia

  2011cited by this paper
• The use of baseline covariates in crossover studies.

  2010cited by this paper
• Differential Effects of p38 Mitogen-Activated Protein Kinase and Cyclooxygenase 2 Inhibitors in a Model of Cardiovascular Disease

  2009cited by this paper
• Performance Characteristics for Some Typical QT Study Designs Under the ICH E‐14 Guidance

  2008cited by this paper
• Concentration‐QT Relationships Play a Key Role in the Evaluation of Proarrhythmic Risk During Regulatory Review

  2008cited by this paper
• Appearance of Double Peaks in Plasma Concentration–time Profile after Oral Administration Depends on Gastric Emptying Profile and Weight Function

  2008cited by this paper
• The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs Step 5 NOTE FOR GUIDANCE ON THE CLINICAL EVALUATION OF QT/QTc INTERVAL PROLONGATION AND PROARRHYTHMIC POTENTIAL FOR NON- ANTIARRHYTHMIC DRUGS (CHMP/ICH/2/04) TRANSMISSION TO CHMP

  2002cited by this paper

• Sex differences in drug-induced QT prolongation

  2020cites this paper
• Assessing QT/QTc interval prolongation with concentration-QT modeling for Phase I studies: impact of computational platforms, model structures and confidence interval calculation methods

  2018cites this paper
• Evaluating cardiac risk: exposure response analysis in early clinical drug development

  2018cites this paper
• A Study to Assess the Proarrhythmic Potential of Mirtazapine Using Concentration‐QTc (C‐QTc) Analysis

  2018cites this paper
• Estimation of QT interval prolongation through model-averaging

  2017cites this paper
• QTc Exposure–Response Modeling as a Primary Methodology for Proarrhythmic Cardiac Safety Assessments

  2017cites this paper
• Balancing the Need for Personalization of QT Correction and Generalization of Study Results: Going Beyond Thorough QT Studies

  2017cites this paper
• Can an early phase clinical pharmacology study replace a thorough QT study? Experience with a novel H3-receptor antagonist/inverse agonist

  2016cites this paper
• The thorough QT study – do we need more of the same?

  2016cites this paper
• Emerging treatment options to improve cardiovascular outcomes in patients with acute coronary syndrome: focus on losmapimod

  2015cites this paper